Financial Daily from THE HINDU group of publications
Tuesday, Apr 26, 2005

News
Features
Stocks
Port Info
Archives
Google

Group Sites

Corporate Results - Pharmaceuticals


Venus Q4 net jumps to Rs 1.5 cr

Our Bureau

Mumbai , April 25

VENUS Remedies Ltd has reported a jump in profit after tax at Rs 1.48 crore for the fourth quarter ended March 2005 from Rs 0.37 crore in the year-ago period.

Total income for the quarter was Rs 10.82 crore (Rs 6.17 crore).

For the full year the company's profit after tax moved up to Rs 4.1 crore from Rs 1.26 crore. Total income was Rs 34.48 crore (Rs 23.91 crore).

The company, which is into formulations, said its focus is to develop new high-value, low-volume formulations and their commercial launch. During 2004-05, it launched 10 new formulations developed in-house in anti-cancer, cephalosporins and FDC segments.

"Venus has a number of other new formulations in various stages of development in its R&D section, including some under clinical trials, for which patents will be filed shortly," the company said in a news release.

Negotiations are in process with three multinational companies, for global launch of a new, innovative formulation developed by the company.

The company is setting up a manufacturing facility in Baddi, Himachal Pradesh, with eight dedicated sections for catering to global markets of super speciality segments of the pharma industry.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page


Stories in this Section
MTNL net up 5.26 pc in Q4


Siemens clocks 89 pc rise in Q2 net, to pay Rs 4.50 interim
Elgi Equipments full-year net profit down 40 pc
MRPL 2004-05 net up 85% at Rs 850 cr
Strides posts 32 pc rise in Q1 net
Venus Q4 net jumps to Rs 1.5 cr
VTM net up, to pay Rs 5.50
HCL Tech Q3 net income up 25 pc


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line